Business Context and Reporting Period
Company: SMX (Security Matters) Public Limited Company
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Six months ended June 30, 2025
Business Overview: SMX develops proprietary technology integrating chemistry, physics, and computer science to provide material tracking, authentication, and supply chain transparency. The company utilizes sub-molecular markers and blockchain ledgers to track materials from origination to recycling, targeting ESG goals and circular economy transitions.
Key Financial Metrics
| Metric (US$ in thousands) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Revenue | Not disclosed (Substantial revenue not yet generated) | Not disclosed |
| Operating Loss | (23,751) | (9,256) |
| Net Loss | (24,621) | (10,886) |
| Net Loss Attributable to Shareholders | (23,638) | (10,693) |
| Cash and Cash Equivalents (as of June 30, 2025) | 750 | 2,343 (as of Dec 31, 2024) |
| Net Cash Used in Operating Activities | (4,145) | (4,536) |
| Net Cash Provided by Financing Activities | 2,689 | 4,636 |
| Accumulated Losses (as of June 30, 2025) | ~106,000 | ~62,000 (as of June 30, 2024) |
Expense Breakdown (Six Months Ended June 30, 2025):
- General and Administrative: $18,656 (Driven by $12,580 in share-based compensation)
- Selling and Marketing: $1,380
- Research and Development (Net): $1,640
- Amortization: $2,075 (New recognition of intangible assets)
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by 126% to $24.6 million, primarily due to a 157% increase in G&A expenses (largely share-based compensation) and the initiation of amortization expenses ($2.1 million) which were nil in the prior period.
- Finance Items: Finance income increased 515% to $9.9 million, and finance expenses increased 232% to $10.7 million, driven by warrant revaluations and foreign exchange fluctuations.
- Capital Structure: The company executed multiple reverse stock splits (75:1, 28.5:1, 4.1:1, and 7:1) between July 2024 and August 2025 to maintain Nasdaq listing compliance. All financial data is presented post-split.
- Equity Grants: In August 2025, the Incentive Equity Plan was amended to authorize an additional 7.13 million shares, with 5.63 million RSUs and 1.5 million options granted to executives and consultants.
Outlook, Risks, and Contingencies
Going Concern Warning
The financial statements contain an explanatory paragraph regarding substantial doubt about the Company's ability to continue as a going concern. The company has incurred accumulated losses of $106 million and relies on external financing to fund operations. Cash on hand as of June 30, 2025, was only $750,000.
Liquidity and Financing
- Recent Funding: Post-balance sheet, the company raised approximately $7.1 million in convertible notes (July/August 2025) and signed an agreement for up to $11 million in additional convertible promissory notes in August 2025.
- Debt Obligations: The company has approximately $14.5 million in payables related to the 2023 business combination and $7.7 million owed to lenders/investors. It is negotiating extensions or conversions of these liabilities.
Legal Proceedings
The company is engaged in arbitration with R&I Trading regarding a terminated $5 million contract for supply chain transparency technology. R&I Trading demands restitution of paid amounts; SMX alleges breach of contract and seeks damages. The outcome is currently uncertain.
Other Risks
- Revenue Generation: The company has not yet generated substantial revenue from technology sales, with long sales cycles targeting multinational conglomerates.
- Foreign Exchange: Significant exposure to ILS, AUD, and SGD fluctuations against the USD.
- Intellectual Property: Contingent liabilities exist for government grants (Israel Innovation Authority) and royalty payments to Isorad Ltd. based on future revenues or M&A events.
Investor Verification Checklist
- Going Concern Status: Verify the success of ongoing debt negotiations and the ability to secure the full $11 million August 2025 convertible note financing.
- Revenue Pipeline: Assess the status of the R&I Trading arbitration and the progress of commercial agreements with multinational clients to determine if revenue recognition is imminent.
- Dilution Risk: Review the terms of recent convertible notes (August and May 2025) and the August 2025 equity grant plan to understand potential dilution to existing shareholders.
- Debt Covenants: Examine the specific default triggers and conversion prices in the Abri Advisors, PMB Partners, and 1800 Diagonal loan agreements.
- Stock Split History: Confirm that all share counts and per-share metrics are adjusted for the four reverse stock splits executed between 2024 and 2025.